NAV-006 / Navrogen - LARVOL DELTA

NAV-006: A next-generation rituximab targeting CD20 for the treatment of B-cell lymphomas immunosuppressed by MUC16/CA125 (AACR 2024) - "In this study we demonstrated that CA125 binds to and suppresses the activity of rituximab, tafasitamab as well as the bispecific mosunetuzumab and glofitamab antibodies, which are approved for treating cases with indolent disease. In an in vivo model of human B-cell lymphoma, NAV-006 showed superior efficacy compared to parent rituximab. These data warrant further investigation of NAV-006 as a next generation anti-CD20 antibody that could improve upon the efficacy of antibody-mediated therapies used to treat NHL patients with high levels of CA125."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • FCGR3A

Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo. (PubMed, Antib Ther) - "Additionally, CA125/MUC16 bound to newer antibody-based lymphoma treatment agents, including obinutuzumab and tafasitamab, suppressing their immune effector functions. Bispecific antibodies mosunetuzumab and glofitamab also exhibited reduced cytotoxicity in the presence of CA125/MUC16. These findings suggest that NAV-006 could improve therapeutic efficacy in B-cell lymphomas, particularly in patients with elevated CA125/MUC16 levels."

Journal • Preclinical • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • MUC16

Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Annual Meeting (PRNewswire) - "Navrogen, Inc...will be presenting preclinical data on its next-generation anti-CD20 antibody, NAV-006, and ICAM-1 refractory antibody-drug conjugate platform at the 2024 American Association for Cancer Research (AACR) Conference in San Diego, California, on April 8-9...Navrogen will present data showing NAV-006's superior efficacy over rituximab in animal models of human NHL. Navrogen's screening technology has also found that CA125 inhibits other regulatory approved canonical and bispecific antibodies targeting CD19 and CD20 in relapsed/refractory NHL, underscoring a broader impact that CA125 has on biological drugs....Navrogen will also present the Humoral Immuno-Oncology (HIO) technology that has uncovered the tumor-produced protein ICAM-1, which binds to IgG1-type antibodies and inhibits their immune effector activity."

Preclinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression. (PubMed, Oncol Lett) - "Rituximab (RTX) is a CD20-targeting antibody that is the standard-of-care for patients with non-Hodgkin Lymphoma (NHL) cases. Furthermore, the study characterized an RTX variant, named NAV-006 (RTX-N109D), which was more refractory to the immunosuppressive effects mediated by CA125 as evidenced by its reduced CA125 interaction and increased activity of ADCC and CDC when compared with parent RTX. Taken together, these findings warranted further investigation on NAV-006 as a next generation anti-CD20 antibody that could improve the efficacy of parent RTX in NHL patients with high levels of CA125."

Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • MUC16

[VIRTUAL] Block-Removed Immunoglobulin Technology (BRITE) to enhance rituximab effector function by counteracting CA125/MUC16-mediated immunosuppression (AACR 2021) - "Here, we demonstrate that NAV-006 is more refractory to the immunosuppressive effects mediated by CA125 as shown by its reduced CA125 interaction and increased HIO activity. These data warrants further investigation of NAV-006 as a next generation anti-CD20 antibody that could improve upon the efficacy of the parent rituximab in NHL patients with high levels of CA125."

Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • MUC16